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1. Introduction
The ability to reprogram somatic cells into pluripotent stem cells has presented a significant
advancement in stem cell research. This technique enables derivation of induced pluripotent
stem (iPS) cells from any individual having a unique genotype. iPS cells can be derived from
human somatic cells such as fibroblasts, keratinocytes or blood cells. Since, the production of
iPS cell lines does not require the destruction of human embryos as in the production of the
human embryonic stem cells (hESCs), the legal and ethical issues associated with hESCs can
be at least partly avoided. The characteristics of iPS cells are very similar to those of pluripotent
hESCs in many respects, including cell morphology, immortal growth characteristics in
culture, expression of pluripotent markers, and differentiation potential. The iPS cells com‐
bined with the various differentiation protocols developed enable the production of genotype
specific cell types. This feature enables also to produce disease-specific iPS cell lines from
patients bearing defined genetic mutations. Traditionally, it has been challenging to study
genetic cardiac diseases because cardiomyocytes from the heart biopsies of patients are
difficult to obtain and the procedure carries a high risk. Additionally these cardiomyocytes do
not survive long in culture. Animal models, mostly developed in rodent, have aided in
elucidating the basic mechanisms of several genetic cardiac diseases. The disadvantages of
small animal models are marked differences in anatomy and physiology of the cardiovascular
system in comparison to humans. Rodent models are far from ideal when used in the identi‐
fication of contractile deficits and signals that initiate pathological growth [1]. Furthermore,
the results obtained from neonatal rat cell experiments can be problematic because these cells
possess different relative receptor subtypes and cell-signaling mechanisms. It will thus be
especially important to investigate functional consequences of genetic cardiac diseases in
human cardiomyocytes in which the functional effects of specific proteins have been adjusted
to optimize electrical properties, contractile efficiency and power output of larger hearts [2].
© 2013 Pekkanen-Mattila et al.; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Genetic cardiac diseases, such as long QT syndrome, belong to a severe class of diseases which
are unpredictable, have variable clinical picture ranging from asymptomatic to sudden cardiac
death and lack specific medication. These inherited arrhythmic diseases are caused by single
mutations which are relatively common in population. Earlier we did not have in vitro models
for these diseases, but with the aid of iPS cell derived cardiomyocytes genetic cardiac diseases
can now be modeled in cell culture. The patient specific iPS cell derived cardiomyocytes have
been demonstrated to manifest the disease-associated electrophysiological abnormalities in a
dish [3-6]. Therefore, these cells allow researchers to study and understand disease mecha‐
nisms more readily as well as to investigate the effects of different chemical compounds on
the electrophysiology of the cardiomyocytes. In addition to basic research, iPS cell derived
cardiomyocytes would provide an effective tool for novel drug or treatment discovery.
However, before iPS cell derived cardiomyocytes are ready to be considered for use as disease
models, the cells produced need to be confirmed to exhibit the essential functional character‐
istics of human cardiomyocytes.
In this chapter, the production and the characterization of patient specific iPS cell derived
cardiomyocytes is described. In addition, we discuss the genetic cardiac disease models so far
developed based on iPS technique, their demands, advantages and disadvantages. Further‐
more, the future applications for iPS cell derived cardiomyocytes are discussed.
2. Production of disease specific iPS cell lines
The discovery of cellular reprogramming as a technology to generate iPS cells offers a potential
solution to the challenge when studying genetic cardiac diseases. In this approach, human
adult somatic cells are reprogrammed into stem cells offering comparable function to human
pluripotent ESCs in their ability to develop differentiated progeny from all developmental
lineages of the human being. When somatic cells are reprogrammed to iPS cells, they shut
down the expression of genes specific for that somatic cell type and activate genes that maintain
pluripotency. Once reprogramming has occurred, endogenous counterparts of the exoge‐
nously supplied reprogramming factors are activated, indicating that exogenous factors are
only required for the induction, not for the maintenance of pluripotency [7]. Up to date, various
human somatic cell types, including fibroblasts, keratinocytes, and different blood cells have
been reprogrammed to iPS cells [7-11].
The initial methods used to generate iPS cells involved the retroviral overexpression of four
transcription factors Oct4, Sox2, Klf4, and c-myc observed to be essential in maintaining
pluripotency of hESCs [7, 12]. Another set of four transcription factors Oct4, Sox2, Nanog, and
Lin-28 was also found to induce pluripotency [9]. Efficient retro- and lentiviral vector systems
that have been most widely used to generate iPS cells have several drawbacks including the
possibility of proviral genomic integration, which may cause both the reactivation of silenced
exogenous genes and the alteration of genomic integrity, thereby increasing the risk for
tumorigenesis [12, 13]. Since the seminal discovery the development in this field has been rapid
and numerous alternative strategies have been applied to improve the reprogramming safety,
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efficiency and kinetics as well as to generate iPS cells without viral integration in the genome
(Table 1). The nonintegrating reprogramming methods developed thus far include adeno- and
sendai viruses, plasmid- and episomal vector-based approaches, excision systems of integrat‐
ed transgenes such as Cre/loxP recombination or PiggyBac transposition, and delivery of
reprogramming factors directly as RNAs, proteins and chemicals. However, most of these
nonintegrating approaches are still highly inefficient when compared to the original retro- or
lentiviral reprogramming systems with the exception of nowadays widely used sendai virus
reprogramming method.
Methods Efficiency % Details References
Retroviral vectors Medium, 0.01-0.5 Multiple integration, incomplete silencing,
tumorigenicity possible
[7]
Lentiviral vectors Medium, 0.1-1 Multiple integration, incomplete silencing,
tumorigenicity possible
[9]
Adenoviral vectors Low, 0.001 Non-integrating, however integrated
vector-fragment possible
[14]
Sendaiviral vectors Medium, 0.01-1 Non-integrating, integrated vector-
fragment possible, T sensitive Sendai
vector allowing removal of the virus
[15]
Plasmids Low, 0.001 Occasional integration, simple transfection [16]
OriP/EBNA-1
episomal vectors
Low, 0.0003 Non-integrating, long-term persistent
transcription
[17]
Minicircle DNA
episomal vectors
Low, 0.005 Non-integrating, multiple transductions
needed
[18, 19]
Cre/loxP system Medium, 0.01-1 Integration but excisable, inefficient loxP
site excision, screening needed,
tumorigenicity possible
[20]
PiggyBac system Medium, 0.1 Precise excision possible, screening
needed
[21, 22]
RNAs High, 1 Non-integrating, DNA-free, multiple
transfection needed
[23, 24]
Protein Low, 0.001 Non-integrating, DNA-free, long-term
treatment required, genetic abnormality
possible
[25]
Factors +
small molecules
High, >1 Non-integrating, DNA-free, long-term
treatment required, abnormal signaling
pathway possible, virus used
[26]
Table 1. Overview of the reprogramming methods for the generation of iPS cells.
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3. Cardiomyocyte differentiation
Cardiomyocytes have been differentiated from the hESCs over a decade [27, 28] and multiple
cardiac differentiation methods have been developed. The differentiation methods developed
for hESC derived cardiomyocytes have been proven to be applicable also for cardiac differ‐
entiation of iPS cells.
Overall the differentiation event of hESC and iPS cell derived cardiomyocytes is quite rapid,
10-20 days regardless of the differentiation method used. However, all the differentiation
methods share common problems, including uncontrolled differentiation and low differen‐
tiation rates. With common differentiation methods the cardiomyocyte yield is between ~1-25
% of the total cell number [28-30]. In addition, the cardiomyocyte differentiation efficiency has
been shown to vary markedly between different stem cell lines [31].
All  differentiation methods end up with a heterogeneous cell  population.  In addition to
the  other  cell  types,  the  differentiated  population  includes  all  cardiomyocyte  subtypes;
ventricular, atrial and nodal –like cells [32]. The ventricular cells form usually the majori‐
ty of differentiated cells (60-80%), atrial cells form usually 10-40 % of the population and
only <5% of cells are nodal-like cells [32, 33]. However, these numbers can differ depend‐
ing on the cell line used [34].
The cardiac differentiation methods are lately reviewed [35] and described in Figure 1.
4. Transdifferentiation of fibroblasts into cardiac cells
Murine fibroblasts can be reprogrammed directly into cardiomyocytes by overexpression of
Gata4, Mef2c and Tbx5 (GMT) [36]. This combination of factors has been reported to convert
murine cardiac fibroblasts and tail tip fibroblasts into spontaneous beating cells having
cardiomyocyte expression profiles. In addition, epigenetic status is typical for cardiomyocytes
in these cells. However, Chen and co-workers have shown this method to be inefficient [37].
Overexpression of GMT factors resulted in an increase in cardiac troponin expression but
spontaneous action potentials were lacking even though 22% of the cells exhibited voltage-
dependent calcium currents.
A lot of effort has been done to transdifferentiate human fibroblasts into cardiomyocytes. So
far spontaneously beating human cells have not been obtained. However, with transcription
factors mesoderm posterior (MESP) homolog and mammalian v-ets erythoblastosis virus E26
oncogene homolog ETS2 cardiomyocyte progenitors expressing cardiac mesoderm marker
KDR have been obtained [38]. It seems that the GMT method alone is not robust enough for
direct reprogramming of human cardiomyocytes. Therefore it has been suggested that
combination of GMT with other transcription factors, mRNAs or small molecules could
provide more efficient reprogramming procedure [39]. In addition, based on animal experi‐
ments it can be concluded that cardiac microenvironment has also important role in reprog‐
ramming [40].
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Figure 1. Generation of disease –specific iPS cell lines and cardiomyocytes. Cardiac differentiation methods can be div‐
ided into three classes; (1) Embryoid body (EB) based, (2) END-2 coculture based or (3) directed differentiation meth‐
ods. Traditionally EB method has been based on spontaneous aggregation of EBs and spontaneous differentiation
[28]. However, lately multiple methods controlling the EB formation has been developed [41] enhancing the reprodu‐
cibility and productivity of the cardiac differentiation. END-2 method can be performed in two ways, either co-cultur‐
ing the hESC or iPS cells in contact with END-2 cells [42] or by using END-2 conditioned media [43]. A lot of effort has
been made in enhancing and defining the cardiac differentiation and this has led to the development of directed dif‐
ferentiation methods with growth factors or small molecules. Activin A and BMP-4 has been used in combination with
monolayer cultures on matrigel to differentiate cardiomyocytes [44]. A temporal modulation of Wnt signaling by us‐
ing small molecules has been proven to an even more robust and, in addition, rather inexpensive method for cardio‐
myocyte differentiation [45]. Directed reprogramming of fibroblasts to cardiomyocytes has been successful with
mouse cells. However, this method has not yet been proven to work with human cells.
5. The assesment of the cardiomyocyte functionality
5.1. Cardiomyocyte characterization at gene and protein level
The first characterization step for the differentiated hESC or iPS cell derived cardiomyocytes
is the observation of spontaneously beating cells. In addition, cardiomyocyte phenotype can
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be assessed at the gene or protein level with cardiomyocyte specific markers such as structural
proteins troponin, alpha-actinin or myosins. The commonly used markers in monitoring the
cardiac differentiation are listed in Table 2.
Cell stage Markers
Pluripotent cells OCT4
Nanog
SOX2
Tra-1-60
SSEA-4
Precardiac/cardiac mesodermal cells Brachyury T
FoxC1
Dkk-1
Mesp1
Flk-1
Cardiac precursor cells KDR
Nkx2.5
GATA4
Tbx5
Isl-1
Mef2c
Hand1/2
Cardiac cells Troponin I and T
Sarcomeric α-actinin
Myosin heavy- and light-
chain (MHC and MLC)
Table 2. Markers used in monitoring the cardiac differentiation.
5.2. Electrophysiological methods
5.2.1. Patch clamp
Traditional way to study the functionality and the electrical activity of the cardiomyocytes is
the patch clamp technique [46]. Originally patch clamp method has been developed to study
ion channels in excitable membranes [47]. In this technique micropipette is attached to the cell
membrane by a giga seal and this can be exploited to measure current changes and voltage
across the membrane. Due to the unique nature of the cardiomyocyte action potential curve,
the ion channel composition and the maturation stage of the cardiomyocyte can be assessed
and therefore the method has been widely used with stem cell derived cardiomyocyte studies.
Key cardiac ion channels (and respective current) involved in the human action potential are
NaV1.5 (INa), KV4.3 (Ito), CaV1.2 (ICa,L) KV11.1 (IKr), KV7.1 (IKs), and Kir2.X (IK1) [48]. The
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cardiac action potential is composed of co-operation of these channels and the action potential
curve can be divided into five different phases (Figure 2). Phase 0 of the action potential is the
depolarization phase of the cardiomyocytes from the negative membrane potential to positive,
called the upstroke. This is followed by phase 1, the short transient repolarization that is
followed by the plateau phase 2. Phase 2 is followed by phase 3, which is the repolarization
back to the resting membrane potential. The resting state of the membrane potential is called
as the phase 4 [49].
As mentioned, cardiac action potential results from the chain reaction of multiple ion channels.
Therefore a malfunction of a single ion channel can be observed from the action potential curve.
Figure 2 presents the parameters which are used in analyzing the action potential. In regard
to analyzing cardiac disease specific cells, the action potential duration plays an important role
because the lengthening of the action potential may lead to severe arrhythmias.
As a method, patch clamp is very informative and provides invaluable data for example for
pharmacological and safety pharmacological studies. However, it is very laborious, needs
highly specialized machinery and, most importantly, dedicated and specialized users. For
these reasons, semi-automated and automated patch clamp machinery are being developed
and would be valuable for cardiomyocyte applications [50, 51].
Figure 2. The phases of the cardiac action potential. ADP50 and ADP90 represent the action potential duration at 50%
and 90% of the repolarization and these parameters are used in determining the duration of the action potential. The
dV/dtmax represents the maximal upstroke velocity and can be used in assessing the electrophysiological phenotype
and maturity stage of the cardiomyocytes.
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5.2.2. Micro electrode array
In addition to the traditional patch clamp technique [46] the micro electrode array (MEA) –
platform [52] offers practical, relative easy and non-invasive technique to assess the electrical
properties of the differentiated cardiomyocytes [53]. Contrary to the patch clamp, the MEA
system measures the electrical activity of a cell population. Therefore the signal resembles
electrocardiogram (ECG) and is called field potential instead of action potential. Even though
the ion channel function cannot be studied in the similar accuracy as with patch clamp, it allows
examination field potential properties, such as cardiac repolarization, and therefore enables
drug effect investigation [53]. During the last years, MEA has been widely used in character‐
ization of hESC- and iPS cell derived cardiomyocytes [31, 54]. MEA has been become a basic
electrophysiological tool and in addition to cardiomyocytes, it has been successfully used also
with other cell types, such as neurons [55].
The MEA system is also applicable in studying cardiac cell responses to pharmaceutical agents
[54]. It also enables cells to be measured repeatedly for longer periods of times e.g. multiple
days or weeks. However, the analysis of MEA measurement data is laborious. Therefore, semi-
automated and automated systems for data analysis have been developed, which makes MEA
system more reliable and efficient tool in research [56].
5.2.3. The assessment of calcium homeostasis
In addition to the unique co-operation of cardiac ion channels, the interaction of calcium-ions
with cardiac structure proteins is another crucial feature in cardiomyocytes that is essential
for the proper function of the heart. In human cardiomyocytes, calcium ion (Ca2+) influx
through L-type calcium channels during the plateau phase triggers the Ca2+-release from the
sarcoplasmic reticulum (SR) which is mediated by the ryanodine receptors (RyR2). The Ca2+
influx together with the release raises the free calcium concentration inside the cardiomyo‐
cytes. In sytosol, free calcium binds to troponin C in the myofilaments and triggers the
machinery which induces the cell contraction. For the cell relaxation to occur, the calcium has
to be rapidly removed from the cytosol. The removal is efficient with the aid of four separate
pathways; sarcoplasmic reticulum Ca2+-ATPase (Serca2a), sarcolemmal Ca2+-ATPase,
sarcolemmal Na+/Ca2+ exchanger and mitochondrial Ca2+ uniport [57].
Similarly as the regular and synchronous chain of action potentials, calcium concentration
fluctuates in the cardiomyocytes. Therefore, with the aid of calcium binding dyes and modern
fluorescence microscope systems, the function and response to pharmaceutical agents of
cardiomyocytes can be monitored. This method is called calcium imaging [58, 59]. The calcium
binding dyes, such as Fura-2 and Fluo-4, can be loaded inside the cardiomyocyte cytosol and
when the calcium ions are released to the cytosol, the ions bind to the dyes and a fluorescence
signal can be detected. When the fluorescence intensity is measured from the single cell, the
calcium handling of the single cardiomyocyte can be monitored and analyzed. From the
calcium imaging data, the beating rate and the function of the calcium handling machinery in
the cardiomyocytes can be assessed. If the calcium is not released or withdrawn from the
cardiomyocyte cytosol in a proper way, irregularity or multiple peaks can be seen in the
calcium imaging curve.
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5.2.4. Force measurement
Recently a lot of effort has been applied to develop measuring systems to understand the
mechanobiology of cardiomyocytes. Force measurement technique can be applied to measure
isometric cardiomyocyte force contraction. A number of parameters can be determined by
using the cardiomyocyte force measurement such as determination of Ca-sensitivity, cooper‐
ativity of force production and maximal Ca-activated force. Kinetics of the contractile re‐
sponses can also be measured such as the actin-myosin turnover kinetics. These parameters
can be useful in the characterization of myofibrillar pathologies of various origin and drug
effects. Most of the currently existing systems are only suitable for the study of cardiac tissue
slices and therefore inappropriate to be used for iPS cell derived cardiomyocytes. Recently,
however, cardiomyocyte force measurement system based on atomic force microscopy (AFM)
was developed which can also be used to study single cardiomyocytes and small clusters of
cardiomyocytes [60]. With the AFM system they were able to measure contractile forces, beat
frequencies and durations of single cardiomyocytes and small cardiomyocyte clusters. The
AFM-based method is also applicable for the screening of cardiac-active pharmacological
agents. Cardiac microtissues have also been constructed using human pluripotent stem cell
derived cardiomyocytes and the contraction force of the beating tissues has been analyzed
with custom made platforms [61, 62].
6. Diseases modeled with iPS cell technique
Since the revolutionary discovery of iPS cells, multiple genetic diseases including cardiac and
neuronal diseases have been modeled with patient specific iPS cell derived cells. Since primary
human cardiomyocytes are not available for research in vitro, iPS cell derived cardiomyocytes
are invaluable tool to study the pathophysiology of severe cardiac diseases and will undoubt‐
edly provide groundbreaking innovations in the future.
6.1. Long QT-syndrome
Long QT-syndrome (LQTS) appears as a genetic or a drug-induced form. It is characterized
by a prolonged cardiac repolarization phase resulting in a prolonged QT interval in the surface
electrocardiogram (ECG). The clinical symptoms of LQTS include palpitations, syncope and
seizures and even sudden cardiac death.
More than 700 mutations in 12 different genes (LQT1–12) have been found to affect genetic
forms of LQTS [63]. However, two of these subtypes account the majority (>90%) of all the
genetically identified LQTSs. Both of these mutations affect potassium channels altering their
proper function. LQTS type 1 (LQT1) is the most common LQTS subtype, resulting from
mutations in the KCNQ1 gene. This gene encodes the α-subunit of the slow component of the
delayed rectifier potassium current (IKs) channel [64]. Individuals with LQT1 typically have
symptoms when the heart rate is elevated e.g. during exercise [65, 66].
LQTS type 2 (LQT2) is due to non-proper functioning of the α-subunit of the rapid delayed
potassium channel (IKr), which is encoded by the human ether-a-go-go-related gene (HERG),
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also known as KCNH2-gene [67]. Contrary to type 1, individuals with LQT2 have clinical
symptoms when the heart rate is slow [65, 66] and syptoms can be triggered e.g. by an alarm
clock during sleep. The drug induced form of LQTS is due to altered function of the HERG-
channel by the drug, therefore this channel has a significant importance during drug devel‐
opment and in safety studies.
The prevalence of the genetic form of LQTS is 1:2,000 in the general population [63]. However,
the penetrance of the clinical symptoms of LQTS is low and there is considerable variation in
phenotypic expression even within families carrying the same mutation [68]. It has also been
suggested, that the population prevalence of milder LQTS mutations might be higher.
Therefore the prevalence of latent or concealed LQTS, i.e. relatively asymptomatic individuals,
would be higher than currently anticipated [69]. Due to this challenging and complex nature
of LQTS, in addition, to the great interest of pharmaceutical industry towards this disease,
multiple reports of iPS cell- based LQTS cell models have been published since 2007 when the
iPS technology was invented.
Moretti and co-workers produced iPS cell derived cardiomycotyes from two patients carrying
a KCNQ1 (R190Q) mutation [6]. In this study, the cardiomyocytes possessed the LQT1
genotype and exhibited prolonged action potential duration. The action potential prolongation
was determined to be caused by the ion-channel trafficking defect resulting in a 70-80% IKs
current density reduction. A β-adrenergic agonist isoproterenol altered the activation and
deactivation kinetics of the IKs and this effect was rescued by the β-blockade [6]. Egashira and
co-workers also produced a disease model for LQTS type 1 [70]. In their study, the iPS cells
were derived from a sporadic patient who did not have a family history of significant QT
interval abnormality. The mutation of the patient in the KCNQ1 was novel (1893delC) and the
cells exhibited prolonged action potential duration in addition to arrhythmogenity.
Similarly results were found with iPS-CM derived from a patient suffering from the severe
LQT type 2 syndrome. The patient had hERG (A614V) mutation and previously presented
episodes of torsade de pointes (TdP), a special type of polymorphic ventricular tachycardia
which is associated with LQTS [4]. The LQT2-cardiomyocytes derived from the patient’s iPS
cells demonstrated increased arrhythmogenicity associated with early after depolarizations
(EADs) [5]. In addition, significant APD prolongation due to a reduced IKr current density
was observed [4]. Arrhytmia and EADs were also induced by a specific HERG-channel blocker
E-4031 to iPS cell derived CM having a hERG (G1681A) mutation. In addition, these cells
exhibited EADs caused by the isoproterenol treatment and these EADs were rescued by β-
blockade [5].
All the aforementioned studies were done with iPS cells derived from the symptomatic LQTS
patients. Nevertheless, similar results have been obtained from patients without severe
symptoms. In the study made in our institute, iPS cell lines were derived from a patient having
a KCNH2 (R176W) mutation and a family history of LQTS. However, this individual was
asymptomatic except for occasional palpitations. iPS cell derived cardiomyocytes from this
patient manifest the phenotype characteristics to LQT2, such as a prolonged repolarization
time and increased arrhythmogenicity [3].
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A human cell model for LQT3 has also been produced and its function and characteristics were
compared with a mouse models which were based on both mouse ESCs and mouse iPS cells
affected with the same disease specific mutation [71]. LQT3 syndrome is due to mutations in
the SCN5A gene, which encodes for the α-subunit of the cardiac sodium (Na+) channel. These
mutations disrupt the inactivation of the Na+ channel during the action potential plateu phase
and this irruption leads to the delay in repolarization and further prolonged QT interval [72].
In addition to LQT3, another kind of cardiac arrhythmia syndromes such as Brugada syndrome
and cardiac conduction disease are associated with mutations in the SCN5A gene. In these
syndromes the mutations are loss-of-function-type whereas LQT3 syndrome they are gain-of-
function-type mutations [72, 73]. The comparison of multiple types of pluripotent stem cell
derived cardiomyocytes showed that all of these models manifest the symptoms of the disease
and, furthermore, the characteristics are similar within both species [71]. iPS cell models for
these loss-of-function diseases have not yet been described.
6.1.1. Timothy syndrome
Timothy syndrome is caused by a single mutation in the CACNA1C-gene. This gene encodes
the main L-type calcium channel, Cav1.2, in the mammalian heart which is essential for the
cardiac action potential and also for cardiomyocyte contraction [74-76]. Timothy sydrome
characterized by LQTS, syndactyly (webbing of fingers and toes), immune deficiency and
autism [77] iPS cell derived cardiomyocytes originating from Timothy syndrome patients
exhibited irregular functional properties typical for the disease [78]. Interestingly, these
irregularities were restored by roscovitine, a compound which increases the voltage-depend‐
ent inactivation of Cav1.2 [78].
6.1.2. Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac
disorder characterized by stress-induced polymorphic ventricular tachycardia in a structurally
normal heart. CPVT is a very severe disease and 30-35% of mutation carriers have had
symptoms (stress-related syncope, seizures or sudden death) by the age of 30. This disease is
caused by mutations in the genes of RyR2 or calsequestrin (CASQ2) which is a regulatory
calcium-buffering protein associated with RyR2 in the SR [79-82].
Multiple iPS-based CPVT disease models have been published, most of them having the
disease specific mutation in the RyR2 gene while [83-85] and one having the mutation in
the  CASQ2  gene  [86].  The  congruent  result  from  these  CPVT  model  studies  was  the
occurrence of delayed after depolarizations (DADs) and arrhythmias which are caused by
the aberrant  diastolic  Ca2+  from the SR.  Notably the model  with RyR2-P2328S mutation
also exhibited early after depolarizations (EADs) in addition to DADs suggesting suggest‐
ing another pathophysiological mechanism for CPVT [85]. Intriguing finding was also the
effect of dantrolene in rescuing the arrhythmogenic phenotype [84].
Disease Models for the Genetic Cardiac Diseases
http://dx.doi.org/10.5772/55773
425
6.1.3. Cardiomyopathies
Mutations in the genes expressed in the cardiomyocytes can cause heart diseases known as
cardiomyopathies. Cardiomyopathies are currently categorized into the following four classes:
arrythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, hypertrophic
cardiomyopathy, and restrictive cardiomyopathy [87]. Cardiomyopathies that are associated
with mutations in genes encoding for sarcomeric proteins are a frequent cause of heart failure.
iPS cells have been used to generate cardiomyocytes from patients in a family with inherited
dilated cardiomyopathy (DCM) [88]. The researchers generated a large number of individual-
specific cardiomyocytes from a family carrying a deleterious point mutation (R173W) in
TNNT2, a gene encoding for a sarcomeric protein cardiac troponin T, which regulates
cardiomyocyte contraction. When compared to cardiomyocytes derived from iPS cells of
healthy controls within the same family, the researchers showed that cardiomyocytes derived
from iPS cells of DCM patients exhibited an increased heterogenous myofilament organization
due to abnormal distribution of α-actinin, compromised ability to regulate calcium flux, and
decreased contraction force. When DCM specific cardiomyocytes were stimulated with a β-
adrenergic agonist, the cells showed characteristics of cellular stress such as reduced beating
rates, compromised contraction, and a greater number of cells with abnormal sarcomeric α-
actinin distribution. The authors also showed that the function of DCM-specific cardiomyo‐
cytes was improved with the treatment with β-adrenergic blockers or overexpression of
Serca2a.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is another genetic cardiomyop‐
athy characterized by replacement of cardiomyocytes by adipose and fibrous tissue leading to
right ventricular failure, arrhythmias and even sudden death [89]. Twelve different genes have
been linked to ARVC and all these encode cardiac cell adhesion proteins resulting in dysfunc‐
tional cardiac desmosomes. Cell adhesion proteins resulting in ARVC include plakoglobin
(JUP), desmoplakin (DSP) and plakophilin 2 (PKP2). Patient specific iPS cells have been
generated from an ARCV patient carrying a PKP2 mutation and having clinical manifestations
of the disease [90]. ARVC specific cardiomyocytes revealed reduced amount of desmosomal
proteins and more lipid droplets in the cardiomyocytes compared to control cardiomyocytes
thus presenting the abnormalities observed in ARCV patients.
The third form of cardiomyopathy, hypertrophic cardiomyopathy (HCM), is a complex
autosomal-dominant disease and the affected individuals acquire cardiac hypertrophy
without external stimuli. Cardiac hypertrophy can be induced by different exogenous factors
such as hypertension and valvular disease and even by severe exercise [91]. Affecting in 1 in
500 individuals within the general population, genetic HCM is the most common inherited
cardiovascular disorder and the leading cause of sudden cardiac death in adolescents and
young adults, especially in atheletes [92-94]. The majority of gene mutations associated with
HCM occur in 13 sarcomere-related genes where several hundred mutations have been
identified [94-97]. Typically cardiac hypertrophy affects the left ventricle and the interventric‐
ular septum and may eventually lead to left ventricular outflow tract obstruction, arrythmias,
diastolic dysfunction, and sudden death. Other hallmark features are myocyte disarray and
fibrosis [94-97]. The hypertrophic process in cardiomyocytes is characterized by morphological
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changes including increase in protein synthesis, enhanced sarcomere reorganization as well
as activation of specific cardiac genes [98-100].
iPS cell technology has not yet been reported to model HCM. However, iPS cells were used to
generate cardiomyocytes from two LEOPARD syndrome patients carrying mutation in the
PTPN11 gene encoding for the SHP2 phosphatase [101]. LEOPARD syndrome is an autosomal-
dominant developmental disorder belonging to inherited RAS-mitogen-activated protein
kinase signalling diseases. A major disease phenotype of the LEOPARD syndrome patients is
HCM [102]. The iPS cell derived cardiomyocytes from LEOPARD syndrome were larger, had
a higher degree of sarcomeric organization as well as preferential localization of NFATC4 in
the nucleus when compared to iPS cell derived cardiomyocytes from healthy sibling of the
LEOPARD syndrome patient thus presenting some indications of hypertrophy in patient
specific cardiomyocytes.
7. Challenges with iPS cell technology and disease modeling
There are still several challenges that need to be carefully considered when designing disease
modeling studies with specialized cell types derived from iPS cells. One potential challenge
relates to the reactivation of silenced exogenous transgenes in the iPS cells or in their differ‐
entiated derivatives leading to the altered genomic integrity which may have unknown effects
on the differentiation potential and characteristics of differentiated cell types. Efforts to
improve the reprogramming methods have led to the technical development of nonintegrating
approaches for iPS cell generation which will eliminate this risk in the future iPS cell lines and
their differentiated derivatives. The nonintegrating sendai virus tehnique is already widely
used in the generation of iPS cells. Regular monitoring of exogenous genes in iPS cells lines
generated by using the integrating techniques is advisable.
Many genetic cardiac diseases are complex demonstrating huge clinical heterogeneity even
within families and patients having the same mutation. In addition, reprogrammed cells carry
genetic alterations that have accumulated through life, thus there is a risk that the variance
overwhelms the ability to detect the authentic mechanisms in the pathophysiology of the
disease. Thus, it will be essential to investigate adequate number of iPSC lines and patients to
be able to demonstrate the common features of the cardiac disease phenotype. Further, it may
be advantageous to initially compare the characteristics of cardiomyocytes from patients
having severe symptoms.
Most likely in many genetic cardiac diseases various cell types in the heart contribute to the
pathophysiological responses of the disease, thus there is a risk that it is impossible to
recapitulate the features of the disorder by using solely cardiomyocytes. A 3D human heart
tissue model with proper composition of cardiomyocytes, endothelial cells, fibroblasts, smooth
muscle cells as well as neurons has not been developed but in recent years the advancement
in this field of research has been rapid and hopefully in future we have besides cell models
authentic tissue models to study genetic cardiac diseases.
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The current cardiomyocyte differentiation protocols generate cells lacking full maturity when
compared to human adult cardiomyocytes. This may lead to a situation where it is impossible
to detect some molecular or functional basis of the cardiac disease. To reduce this risk it will
be advisable to use control cells to compare diseased cardiomyocytes to healthy cardiomyo‐
cytes. For reliable and reproducible modeling of cardiac diseases it is necessary to have
preferable multiple iPS lines from healthy controls. For monogenic diseases the use of iPS cells
derived from the healthy family members would be favorable for minimizing the effect of
genetic variation. However, iPS cells from family members are not always available. On
possibility to overcome this challenge is to use genome editing techniques such as zinc finger
nuclease technology and transcription activator–like effectors (TALEs) in modifying the iPS
cells [103, 104]. With these methods, it is possible to correct a targeted point mutation in human
iPS cells and produce control cells for disease specific iPS cells.
8. Conclusions
The most relevant human disease model uses cells of human origin, of the appropriate cell
type, and with the identical genetic background as the patients. Traditionally, this approach
in cardiac diseases has been out of reach as human cardiomyocytes are not easily procured
and their propagation in vitro is extremely problematic. The revolutionary discovery of cellular
reprogramming as a technology to generate iPS cells enables the production of patient specific
cell types such as cardiomyocytes which can be used as authentic and relevant human cell
models to study the pathophysiology of genetic cardiac diseases as well as in drug discovery
and safety assays. The most relevant aspects in disease modeling are to show that the produced
disease specific cell type bears the disease causing mutation and further to present the
functional consequences of the mutant protein. Here we have reviewed the genetic cardiac
diseases modeled thus far by using the iPS cell technology. Worthwhile of noticing is that the
era of iPS cells in disease modeling is just in the very beginning. As the production of iPS cells
and cardiomyocytes with more mature phenotype and the methods available for the functional
characterization of cardiomyocytes continue to develop the future looks bright for modeling
genetic cardiac diseases. Importantly these models will be extremely valuable for drug
discovery and toxicology in the future.
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